Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients

Ann Oncol. 2020 Dec;31(12):1782-1784. doi: 10.1016/j.annonc.2020.09.003. Epub 2020 Sep 14.

Authors

O Mir¹, S Watson², C Massard², A Le Cesne³, K A Benhadji⁴, J C Soria²

Affiliations

¹ Gustave Roussy Cancer Institute, Sarcoma Group, Villejuif, France. Electronic address: olivier.mir@gustaveroussy.fr.
² Gustave Roussy Cancer Institute, Department of Drug Development (DITEP), University Paris Saclay, Villejuif, France.
³ Gustave Roussy Cancer Institute, Sarcoma Group, Villejuif, France.
⁴ Eli Lilly and Company, New York, USA.

PMID: 32941988
DOI: 10.1016/j.annonc.2020.09.003

No abstract available

Publication types

Letter

MeSH terms

Benzazepines*
Humans
Indazoles
Pyrimidines
Sarcoma* / drug therapy
Sulfonamides

Substances

Benzazepines
Indazoles
Pyrimidines
Sulfonamides
pazopanib
crenigacestat